Squarepoint
BCRX icon

Squarepoint’s BioCryst Pharmaceuticals BCRX Stock Holding History

Squarepoint’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-49,500
Closed -$372K – 4581
2024
Q4 		$372K Buy
+49,500
New +$376K ﹤0.01% 3992

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Squarepoint's BCRX Position: Q2 2026 in Review

Squarepoint increased its BioCryst Pharmaceuticals (BCRX) stake by 339% in Q2 2026, buying an estimated $1.22M and bringing the position to 174,714 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2454.

Squarepoint first reported a position in BCRX in Q4 2015 and has held it in 35 quarters since. The position peaked at $12.9M in Q4 2025. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Squarepoint held 174,714 shares of BioCryst Pharmaceuticals worth $1.75M as of Q2 2026.
  • Squarepoint bought 134,949 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.22M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2454 holding.
  • Squarepoint first reported a position in BioCryst Pharmaceuticals in Q4 2015 and has held it in 35 quarters since.
  • Squarepoint's BioCryst Pharmaceuticals position peaked at $12.9M in Q4 2025.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.